Gilead Sciences (GILD) Share-based Compensation (2009 - 2026)

Gilead Sciences has reported Share-based Compensation for 18 years, with the latest figure at $218.0 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 4.31% year-over-year to $218.0 million; the trailing twelve-month figure through Mar 2026 stood at $903.0 million (up 5.37% YoY), and the FY2025 full-year result was $894.0 million, up 7.07% from the prior year.
• Share-based Compensation for Q1 2026 stood at $218.0 million, down from $230.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $230.0 million in Q3 2025, with the low at $130.0 million in Q1 2022.
• Historically, Share-based Compensation has averaged $197.1 million across 5 years, with a median of $202.0 million in 2023.
• Annual changes were most pronounced in 2022 — Share-based Compensation slipped 6.47% — and 2023, when it increased 26.92%.
• Gilead Sciences' Share-based Compensation stood at $174.0 million in 2022, then grew by 15.52% to $201.0 million in 2023, then increased by 10.45% to $222.0 million in 2024, then increased by 3.6% to $230.0 million in 2025, then dropped by 5.22% to $218.0 million in 2026.
• The last three Share-based Compensation figures came in at $218.0 million (Q1 2026), $230.0 million (Q4 2025), and $230.0 million (Q3 2025), per Business Quant data.